255 related articles for article (PubMed ID: 28724435)
1. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.
Chen S; Wang H; Huang YF; Li ML; Cheng JH; Hu P; Lu CH; Zhang Y; Liu N; Tzeng CM; Zhang ZM
Mol Cancer; 2017 Jul; 16(1):128. PubMed ID: 28724435
[TBL] [Abstract][Full Text] [Related]
2. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ.
Chan SW; Lim CJ; Huang C; Chong YF; Gunaratne HJ; Hogue KA; Blackstock WP; Harvey KF; Hong W
Oncogene; 2011 Feb; 30(5):600-10. PubMed ID: 20972459
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway.
Lim SK; Orhant-Prioux M; Toy W; Tan KY; Lim YP
FASEB J; 2011 Sep; 25(9):3004-18. PubMed ID: 21642474
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.
Li Z; Lim SK; Liang X; Lim YP
J Biol Chem; 2018 Dec; 293(52):20014-20028. PubMed ID: 30442712
[TBL] [Abstract][Full Text] [Related]
5. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
6. The Evaluation of WBP2NL-Related Genes Expression in Breast Cancer.
Nourashrafeddin S; Aarabi M; Modarressi MH; Rahmati M; Nouri M
Pathol Oncol Res; 2015 Apr; 21(2):293-300. PubMed ID: 25417742
[TBL] [Abstract][Full Text] [Related]
7. Biophysical basis of the binding of WWOX tumor suppressor to WBP1 and WBP2 adaptors.
McDonald CB; Buffa L; Bar-Mag T; Salah Z; Bhat V; Mikles DC; Deegan BJ; Seldeen KL; Malhotra A; Sudol M; Aqeilan RI; Nawaz Z; Farooq A
J Mol Biol; 2012 Sep; 422(1):58-74. PubMed ID: 22634283
[TBL] [Abstract][Full Text] [Related]
8. WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma.
Chen S; Zhang Y; Wang H; Zeng YY; Li Z; Li ML; Li FF; You J; Zhang ZM; Tzeng CM
Cell Death Dis; 2018 Mar; 9(3):347. PubMed ID: 29497031
[TBL] [Abstract][Full Text] [Related]
9. Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.
Lim SK; Tabatabaeian H; Lu SY; Kang SA; Sundaram GM; Sampath P; Chan SW; Hong WJ; Lim YP
Cell Death Dis; 2020 Aug; 11(8):669. PubMed ID: 32820148
[TBL] [Abstract][Full Text] [Related]
10. WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
Ren YQ; Wang HJ; Zhang YQ; Liu YB
Cancer Chemother Pharmacol; 2017 May; 79(5):1003-1011. PubMed ID: 28391353
[TBL] [Abstract][Full Text] [Related]
11. WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.
Han Q; Rong X; Lin X; Zhang X; Fan C; Zhao H; Wang E
Cell Death Dis; 2021 Apr; 12(4):384. PubMed ID: 33837178
[TBL] [Abstract][Full Text] [Related]
12. WW domain binding protein 2 (WBP2) as an oncogene in breast cancer: mechanisms and therapeutic prospects-a narrative review.
Liu Y; He E; Zhang Y; Liu Y; Wang Y; Chen S; Wu X; Zeng Y; Leng P
Gland Surg; 2022 Dec; 11(12):1984-2002. PubMed ID: 36654949
[TBL] [Abstract][Full Text] [Related]
13. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
[TBL] [Abstract][Full Text] [Related]
14. The emerging roles of WBP2 oncogene in human cancers.
Tabatabaeian H; Rao A; Ramos A; Chu T; Sudol M; Lim YP
Oncogene; 2020 Jun; 39(24):4621-4635. PubMed ID: 32393834
[TBL] [Abstract][Full Text] [Related]
15. Biophysical analysis of binding of WW domains of the YAP2 transcriptional regulator to PPXY motifs within WBP1 and WBP2 adaptors.
McDonald CB; McIntosh SK; Mikles DC; Bhat V; Deegan BJ; Seldeen KL; Saeed AM; Buffa L; Sudol M; Nawaz Z; Farooq A
Biochemistry; 2011 Nov; 50(44):9616-27. PubMed ID: 21981024
[TBL] [Abstract][Full Text] [Related]
16. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells.
Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2009 Jun; 30(6):937-45. PubMed ID: 19357348
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of E-box binding USF-1 by PI3K/AKT enhances its transcriptional activation of the WBP2 oncogene in breast cancer cells.
Ramos A; Miow QH; Liang X; Lin QS; Putti TC; Lim YP
FASEB J; 2018 Sep; ():fj201801167RR. PubMed ID: 30183375
[TBL] [Abstract][Full Text] [Related]
18. Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription.
Chen S; Wang H; Li Z; You J; Wu QW; Zhao C; Tzeng CM; Zhang ZM
Br J Cancer; 2018 May; 119(2):182-192. PubMed ID: 29937544
[TBL] [Abstract][Full Text] [Related]
19. WBP2 promotes BTRC mRNA stability to drive migration and invasion in triple-negative breast cancer via NF-κB activation.
Lim YX; Lin H; Chu T; Lim YP
Mol Oncol; 2022 Jan; 16(2):422-446. PubMed ID: 34197030
[TBL] [Abstract][Full Text] [Related]
20. Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.
Li J; Liu J; Ren Y; Liu P
Exp Biol Med (Maywood); 2015 Mar; 240(3):324-8. PubMed ID: 25476151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
